Sandhu Premjeet1, 2,Rathore Devashish2, Kataria Sahil1 , Middha Akanksh1
1Seth G. L. Bihani S.D. College of Technical Education,
Institute of Pharmaceutical Sciences and Drug Research,
Sri Ganganagar, Rajasthan, INDIA
2 School of Pharmaceutical Sciences, RGPV University campus,
Bhopal, M.P, INDIA
The blood – brain barrier (BBB) has always presented a challenge to scientists for brain drug targeting . the BBB evolved in such a way that it protects the brain from various foreign substance such as neurotoxins. This mechanism makes the BBB an insurmountable . This mechanism makes BBB an insurmountable barrier for numerous highly essential drugs , including antibiotics, cytostatics and other CNS active drug Drugs may be administered directly into the CNS or administered systematically (e.g. by intravenous injection) for targeted action in the CNS. The major challenge to CNS drug delivery is the blood-brain barrier (BBB), which limits the access of drugs to the brain substance. Various strategies that have been used for manipulating the blood-brain barrier for drug delivery to the brain include osmotic and chemical opening of the blood-brain barrier as well as the use of transport/carrier systems. Other strategies for drug delivery to the brain involve bypassing the BBB. Various pharmacological agents have been used to open the BBB and direct invasive methods can introduce therapeutic agents into the brain substance. It is important to consider not only the net delivery of the agent to the CNS, but also the ability of the agent to access the relevant target site within the CNS. Various routes of administration as well as conjugations of drugs, e.g. with liposomes and nanoparticles are considered. Some routes of direct administration to the brain are non-invasive such as transnasal route whereas others involve entry into the CNS by devices and needles such as in case of intrathecal and intracerebroventricular delivery.